罗格列酮对高糖高脂饮食诱导糖尿病大鼠脂肪肝的治疗作用

目的探讨罗格列酮（RSG）对2型糖尿病（T2DM）大鼠合并脂肪肝的治疗作用。方法建立T2DM合并脂肪肝的大鼠模型，以RSG进行干预治疗。18周末留取肝组织及血清，检测比较各组血糖、血脂、胰岛素、谷丙转氨酶、TNF-α、瘦素等指标及肝脏病理变化和TNF-α在肝脏的表达。结果RSG治疗组大鼠肝脏结构较糖尿病对照组明显好转，TNF-α在肝脏的表达水平降低（P〈0.05），TG、TC、瘦素水平均明显下降（P〈0.05，P〈0.01，P〈0.05）。结论RSG对实验性糖尿病大鼠合并脂肪肝具有一定的治疗作用。

The therapeutic effect of rosiglitazone on fatty liver induced by high-glucose/high-fat diet in T2DM rats

Objective To investigate the effects of rosiglitazone on fatty liver induced by highglucose/high-fat diet. Methods T2DM rat model with fatty liver was established by STZ injection and high fat/high glucose diet. Three groups of female SD rats included normal control（NC, n= 10）, models with（DMR, n = 15） and without （DM-C, n = 15） rosiglitazone treatment for 18 weeks. The liver specimens were prepared for H. E. staining, suda IV-staining and immunohischemistry stain. The levels of fasting serum glucose,insulin,ALT,TNF-α and leptin and the expression of TNF-α in the liver were measured. Results Light and electron microscopy showed that liver tissue panlobular microvascular and macrovascular steatosis and occasional loci of inflammation were improved obviously by rosiglitazone treatment. Rosiglitazone could significantly reduce levels of TG, TC（P〈0.05, P〈0.01）, improve the state of the insulin resistance and reduce the expressive levels of TNF-α and leptin in the liver（P〈0.01, P〈0.01, P〈0.05）. Conclusions Rosiglitazone can efficiently treat the fatty liver in the rat model of type 2 diabetes mellitus with fatty liver.